US1538678A
(en)
*
|
1923-02-24 |
1925-05-19 |
Joseph S Blinn |
Suppository injector
|
US3791385A
(en)
*
|
1972-10-16 |
1974-02-12 |
A Davis |
Catamenial device and applicator thereof
|
CA1339210C
(en)
|
1988-05-31 |
1997-08-05 |
John Lewicki |
Recombinant techniques for production of novel natriuretic and vasodilator peptides
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
EP0478797B1
(en)
|
1990-04-20 |
1995-04-12 |
Hisayuki Matsuo |
Novel physiologically active peptide originating in hog
|
JP3026351B2
(ja)
|
1990-07-13 |
2000-03-27 |
壽之 松尾 |
ブタcnp遺伝子及び前駆体蛋白
|
JP2930380B2
(ja)
|
1990-07-13 |
1999-08-03 |
壽之 松尾 |
ブタ由来新規生理活性ペプチド(cnp―53)
|
JP2977158B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
トリ由来新規生理活性ペプチド(ニワトリcnp)
|
JP2977159B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
カエル由来新規生理活性ペプチド(カエルcnp)
|
JP3026352B2
(ja)
|
1990-09-11 |
2000-03-27 |
壽之 松尾 |
ラットCNPcDNA及び前駆体蛋白
|
JP3026354B2
(ja)
|
1990-09-27 |
2000-03-27 |
壽之 松尾 |
ヒトcnp遺伝子及び前駆体蛋白
|
JP2809533B2
(ja)
|
1991-01-31 |
1998-10-08 |
壽之 松尾 |
Cnp類似体ペプチド
|
CA2102808A1
(en)
*
|
1991-05-10 |
1992-11-11 |
Hanne Bentz |
Targeted delivery of bone growth factors
|
AU6360394A
(en)
|
1993-03-03 |
1994-09-26 |
Mayo Foundation For Medical Education And Research |
Vasonatrin peptide and analogs thereof
|
WO1995005455A1
(en)
*
|
1993-08-13 |
1995-02-23 |
Rijksuniversiteit Te Groningen |
Pharmaceutical composition comprising phosphatase or a derivative thereof
|
DE69432123T2
(de)
|
1993-11-12 |
2004-01-08 |
Genentech, Inc., South San Francisco |
Rezeptor spezifische atrio-natriuretische peptide
|
US5846932A
(en)
|
1993-11-12 |
1998-12-08 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
US5665704A
(en)
|
1993-11-12 |
1997-09-09 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
US6525022B1
(en)
|
1993-11-12 |
2003-02-25 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
EP0763061B1
(de)
|
1994-06-02 |
2002-10-30 |
Forssmann, Wolf-Georg, Prof. Dr. med. |
Verfahren zur herstellung von cardiodilatin-fragmenten, hochgereinigte cardiodilatin-fragmente und zwischenprodukte zu deren herstellung
|
JPH0870875A
(ja)
|
1994-09-05 |
1996-03-19 |
Tosoh Corp |
組換えアルカリフォスファタ−ゼ融合タンパク質
|
US5863782A
(en)
|
1995-04-19 |
1999-01-26 |
Women's And Children's Hospital |
Synthetic mammalian sulphamidase and genetic sequences encoding same
|
US6028055A
(en)
|
1996-10-22 |
2000-02-22 |
Genetech, Inc. |
Receptor selective BNP
|
EP0939770A1
(en)
|
1996-10-22 |
1999-09-08 |
Genentech, Inc. |
Receptor specific brain natriuretic peptide (bnp)
|
WO1998035703A2
(en)
*
|
1997-02-14 |
1998-08-20 |
The Salk Institute For Biological Studies |
Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
|
WO1999046283A1
(en)
|
1998-03-09 |
1999-09-16 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
CA2245903A1
(en)
*
|
1998-09-28 |
2000-03-28 |
Mcgill University |
Use of pex in the treatment of metabolic bone diseases
|
CA2260376A1
(en)
|
1999-02-11 |
2000-08-11 |
Universite De Montreal |
New metalloproteases of the neprilysin family
|
CA2262056A1
(en)
*
|
1999-02-24 |
2000-08-24 |
Guy Boileau |
Composition, methods and reagents for the synthesis of a soluble form of human pex
|
AU2495200A
(en)
|
1999-03-08 |
2000-09-28 |
Genentech Inc. |
Compositions and methods for the treatment of tumor
|
AU772074B2
(en)
|
1999-04-28 |
2004-04-08 |
Vectramed, Inc. |
Enzymatically activated polymeric drug conjugates
|
WO2004011498A2
(en)
|
2002-07-31 |
2004-02-05 |
Conjuchem Inc. |
Long lasting natriuretic peptide derivatives
|
US20040266673A1
(en)
|
2002-07-31 |
2004-12-30 |
Peter Bakis |
Long lasting natriuretic peptide derivatives
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
JP2000327583A
(ja)
*
|
1999-05-17 |
2000-11-28 |
Medei Sci Puraningu:Kk |
骨指向性ホルモン誘導体
|
EP1591453A1
(en)
|
1999-05-17 |
2005-11-02 |
ConjuChem Inc. |
Modified peptides yy and conjugates thereof
|
DE19942230C2
(de)
|
1999-09-03 |
2003-09-25 |
Wolf-Georg Forssmann |
Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen
|
DE60034478T2
(de)
|
1999-11-16 |
2008-01-10 |
Genzyme Corp., Cambridge |
Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
|
EP1248790A1
(en)
*
|
1999-12-17 |
2002-10-16 |
Ariad Pharmaceuticals, Inc. |
Proton pump inhibitors
|
US6407211B1
(en)
|
1999-12-17 |
2002-06-18 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic peptides
|
JP4237375B2
(ja)
|
2000-03-31 |
2009-03-11 |
アスビオファーマ株式会社 |
虚血性疾患の処置又は予防に用いる医薬組成物
|
US6946484B2
(en)
|
2000-04-26 |
2005-09-20 |
Cellegy Pharmaceuticals, Inc. |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
EP1502604A1
(en)
|
2000-04-26 |
2005-02-02 |
Cellegy Pharmaceuticals, Inc |
Use of nitric oxide mimetics in cancer treatment
|
US20050142217A1
(en)
|
2000-04-26 |
2005-06-30 |
Adams Michael A. |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
US7678391B2
(en)
|
2000-04-26 |
2010-03-16 |
Queen's University At Kingston |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
US6830885B1
(en)
|
2000-08-18 |
2004-12-14 |
Phenogene Therapeutiques Inc. |
Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
|
AU2001287429B2
(en)
*
|
2000-08-23 |
2005-08-18 |
Alexion Pharmaceuticals, Inc. |
Method and compositions for promoting osteogenesis
|
US6436386B1
(en)
*
|
2000-11-14 |
2002-08-20 |
Shearwater Corporation |
Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
|
CA2716959A1
(en)
|
2000-12-07 |
2002-06-13 |
Eli Lilly And Company |
Glp-1 fusion proteins
|
JP2002178279A
(ja)
|
2000-12-12 |
2002-06-25 |
Ulvac Japan Ltd |
基板搬送方法
|
AU2002255478A1
(en)
*
|
2001-01-10 |
2002-09-12 |
Pe Corporation (Ny) |
Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
|
JP2002246704A
(ja)
|
2001-02-16 |
2002-08-30 |
Philips Japan Ltd |
電子装置及び回路装置
|
IL142118A0
(en)
|
2001-03-20 |
2002-03-10 |
Prochon Biotech Ltd |
Method and composition for treatment of skeletal dysplasias
|
WO2002092020A2
(en)
|
2001-03-23 |
2002-11-21 |
The Burnham Institute |
Compositions and methods for modulating bone mineral deposition
|
US7888372B2
(en)
|
2001-03-23 |
2011-02-15 |
National Institutes Of Health (Nih) |
Compositions and methods for modulating bone mineral deposition
|
ATE437221T1
(de)
|
2001-05-14 |
2009-08-15 |
Gbp Ip Llc |
Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
|
EP1485707B1
(en)
|
2001-07-16 |
2009-01-14 |
caprotec bioanalytics GmbH |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
US6610025B2
(en)
*
|
2001-08-06 |
2003-08-26 |
The Procter & Gamble Company |
Tampon applicator arrangement
|
BRPI0203172B8
(pt)
|
2001-09-28 |
2021-05-25 |
Nakao Kazuwa |
composição farmacêutica para acondroplasia
|
US20050202442A1
(en)
|
2003-12-15 |
2005-09-15 |
Morris David W. |
Novel therapeutic targets in cancer
|
WO2003054005A2
(en)
|
2001-12-20 |
2003-07-03 |
Phenogene Therapeutiques Inc. |
Bone polypeptide-1
|
ES2545090T3
(es)
|
2001-12-21 |
2015-09-08 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina y GCSF
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
US20030158132A1
(en)
|
2002-01-22 |
2003-08-21 |
Genvec, Inc. |
Method for enhancing bone density or formation
|
CA2478145A1
(en)
|
2002-03-06 |
2003-09-12 |
Cellegy Pharmaceuticals, Inc. |
Formulations and methods of using nitric oxide mimetics in cancer treatment
|
US20050113286A1
(en)
|
2002-03-18 |
2005-05-26 |
Schreiner George F. |
Methods for treating congestive heart failure
|
WO2003079979A2
(en)
|
2002-03-18 |
2003-10-02 |
Scios Inc. |
Method for treating congestive heart failure
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
CA2433479A1
(en)
|
2002-07-22 |
2004-01-22 |
F. Hoffmann-La Roche Ag |
Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
|
US20060110359A1
(en)
|
2002-09-06 |
2006-05-25 |
Juan Sanchez-Ramos |
Cellular delivery of natriuretic peptides
|
WO2004046194A2
(en)
|
2002-11-18 |
2004-06-03 |
Syn X Pharma, Inc. |
Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
|
US7648962B2
(en)
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
PL377813A1
(pl)
|
2002-11-26 |
2006-02-20 |
Biocon Limited |
Modyfikowane związki natriuretyczne, ich koniugaty oraz zastosowania
|
AU2003291867A1
(en)
|
2002-12-03 |
2004-06-23 |
Biomep Inc. |
Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
|
WO2004062555A2
(en)
|
2003-01-13 |
2004-07-29 |
Gudrun Rappold-Hoerbrand |
Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
|
EP1594893A2
(en)
|
2003-02-14 |
2005-11-16 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
US7488713B2
(en)
|
2004-03-18 |
2009-02-10 |
University Of South Florida |
Cancer treatment using C-type natriuretic peptides
|
CA2522709A1
(en)
|
2003-04-17 |
2004-11-04 |
Ciphergen Biosystems, Inc. |
Polypeptides related to natriuretic peptides and methods of their identification and use
|
AU2004257142A1
(en)
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
US7919255B2
(en)
|
2003-06-17 |
2011-04-05 |
Otago Innovation Limited |
Assessment of skeletal growth using measurements of NT-CNP peptides
|
WO2005000095A2
(en)
|
2003-06-20 |
2005-01-06 |
Mayo Foundation For Medical Education And Research |
Isoforms of brain natriuretic peptide
|
WO2005052593A1
(en)
|
2003-10-29 |
2005-06-09 |
The University Of Leicester |
Detection
|
US7431915B2
(en)
|
2003-10-31 |
2008-10-07 |
The Regents Of The University Of California |
Peptides whose uptake by cells is controllable
|
AU2004282984B2
(en)
|
2003-11-13 |
2011-07-14 |
Hanmi Science Co., Ltd. |
Protein complex using immunoglobulin fragment andmethod for the preparation thereof
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
WO2005070446A1
(en)
|
2004-01-15 |
2005-08-04 |
Scios Inc. |
Method for treating cardiac remodeling following myocardial injury
|
US20080182299A1
(en)
|
2004-01-27 |
2008-07-31 |
Compugent Ltd. |
Novel brain natriuretic peptide variants and methods of use thereof
|
EP1730181A2
(en)
|
2004-01-27 |
2006-12-13 |
Compugen USA, Inc. |
Novel brain natriuretic peptide variants and methods of use thereof
|
CN1960758B
(zh)
|
2004-03-31 |
2014-10-22 |
中外制药株式会社 |
关节炎的治疗剂或预防剂
|
EP3446711A1
(en)
|
2004-03-31 |
2019-02-27 |
Kazuwa Nakao |
Composition for increasing body height
|
JP2005292718A
(ja)
|
2004-04-05 |
2005-10-20 |
Furukawa Electric Co Ltd:The |
光導波路、光導波路モジュールおよび光導波路の作成方法
|
DK3404102T3
(da)
|
2004-04-21 |
2021-09-06 |
Alexion Pharma Inc |
Knogletilførselskonjugater og fremgangsmåde til anvendelse heraf til målretning af proteiner mod knogle
|
US20070142339A1
(en)
|
2004-05-10 |
2007-06-21 |
Novacea, Inc. |
Prevention of arterial restenosis with active vitamin d compounds
|
US20070081984A1
(en)
*
|
2005-10-11 |
2007-04-12 |
Shunji Tomatsu |
Compositions and methods for treating hypophosphatasia
|
US7863238B2
(en)
*
|
2004-06-10 |
2011-01-04 |
Saint Louis University |
Proteins with an attached short peptide of acidic amino acids
|
US7972593B2
(en)
|
2004-06-10 |
2011-07-05 |
Saint Louis University |
Delivery of therapeutic agents to the bone
|
US20070081986A1
(en)
*
|
2005-10-07 |
2007-04-12 |
Shunji Tomatsu |
Beta-glucuronidase with an attached short peptide of acidic amino acids
|
ATE496060T1
(de)
|
2004-07-15 |
2011-02-15 |
Univ Queensland |
Proteinartige verbindungen und anwendungen davon
|
WO2006039480A2
(en)
|
2004-09-29 |
2006-04-13 |
The Burnham Institute For Medical Research |
Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification
|
WO2006060641A2
(en)
|
2004-12-01 |
2006-06-08 |
Genzyme Corporation |
Methods for targeted delivery of genetic material to the liver
|
PT2510942E
(pt)
|
2005-04-07 |
2015-12-28 |
Cardiorentis Ag |
Utilização de péptido natriurético para o tratamento de insuficiência cardíaca
|
EP1874816A4
(en)
|
2005-04-26 |
2010-08-25 |
Medimmune Inc |
MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
|
US20070042957A1
(en)
|
2005-08-19 |
2007-02-22 |
Mayo Foundation For Medical Education And Research |
Type v phosphodiesterase inhibitors and natriuretic polypeptides
|
US7470668B2
(en)
|
2005-08-24 |
2008-12-30 |
Enobia Pharma Inc. |
Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
|
CA2621264A1
(en)
|
2005-09-06 |
2007-11-15 |
Zelos Therapeutics, Inc. |
Parathyroid hormone analogues and methods of use
|
US7803901B2
(en)
|
2005-09-16 |
2010-09-28 |
Mayo Foundation For Medical Education And Research |
Polypeptides with natriuresis activity
|
WO2007041645A2
(en)
|
2005-10-03 |
2007-04-12 |
Scios Inc. |
Oxidized human bnp
|
RU2316334C2
(ru)
|
2005-12-19 |
2008-02-10 |
Медитек Индастриз ЛЛС |
Способ активации утраченных двигательных функций, а также определения эффективности их восстановления при повреждении центральной нервной системы
|
US7625564B2
(en)
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
WO2007097923A2
(en)
|
2006-02-20 |
2007-08-30 |
Phylogica Limited |
Method of constructing and screening libraries of peptide structures
|
US8784833B2
(en)
|
2006-06-27 |
2014-07-22 |
Saint Louis University |
Prenatal enzyme replacement therapy for hypophosphatasia
|
AU2007315790A1
(en)
|
2006-06-30 |
2008-05-08 |
Interface Biologics, Inc. |
Bioresponsive polymers
|
US7825092B2
(en)
|
2006-08-08 |
2010-11-02 |
University Of South Florida |
Dendroaspis natriuretic peptide for treatment of cancer
|
TW200817431A
(en)
|
2006-08-08 |
2008-04-16 |
Mayo Foundation |
Diuretic and natriuretic polypeptides
|
MX2009002504A
(es)
|
2006-09-08 |
2009-05-22 |
Mayo Foundation |
Polipeptidos acuareticos y natriureticos que carecen de actividad vasodilatadora.
|
CA2663083A1
(en)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
WO2008088422A2
(en)
|
2006-10-25 |
2008-07-24 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
WO2008058016A2
(en)
|
2006-11-02 |
2008-05-15 |
University Of Virginia Patent Foundation |
Ethoid-containing compounds, methods for preparing ethoid-containing compounds, and methods for use
|
EP2086321B1
(en)
|
2006-11-16 |
2016-08-31 |
Kai Pharmaceuticals, Inc. |
Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
|
US20080181903A1
(en)
|
2006-12-21 |
2008-07-31 |
Pdl Biopharma, Inc. |
Conjugate of natriuretic peptide and antibody constant region
|
CA2680537C
(en)
|
2007-03-12 |
2018-10-16 |
Soheyl Bahrami |
Diagnosis of septic complications
|
EP1985697A1
(en)
|
2007-04-27 |
2008-10-29 |
AM-Pharma B.V. |
Modified phosphatases
|
KR20080098216A
(ko)
|
2007-05-04 |
2008-11-07 |
한미약품 주식회사 |
캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
|
BR122019000505B1
(pt)
|
2007-05-11 |
2022-01-18 |
Alexion Pharmaceuticals, Inc |
Fosfatase alcalina direcionada ao osso, kits e métodos de seu uso
|
WO2008143954A2
(en)
|
2007-05-14 |
2008-11-27 |
Biogen Idec Ma Inc. |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
WO2008154226A1
(en)
|
2007-06-06 |
2008-12-18 |
Boehringer Ingelheim International Gmbh |
Natriuretic fusion proteins
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
US20110077383A1
(en)
|
2007-07-03 |
2011-03-31 |
Medimmune, Llc |
Hinge domain engineering
|
MX2009013372A
(es)
|
2007-07-06 |
2010-02-22 |
Theratechnologies Inc |
Proteinas de fusion bifuncionales de la hormona estimulante de alfa-melanocitos (alfa-msh) y proteina natriuretica atrial (anp) y usos en hipertension y lesion de riñon aguda.
|
WO2009015011A1
(en)
|
2007-07-20 |
2009-01-29 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
EP2190466A4
(en)
|
2007-08-10 |
2011-12-21 |
Burnham Inst Medical Research |
Tissue-specific alkaline phosphatase (TNAP) activators and their use
|
US8933197B2
(en)
|
2007-08-15 |
2015-01-13 |
Amunix Operating Inc. |
Compositions comprising modified biologically active polypeptides
|
US20100204143A1
(en)
|
2007-09-11 |
2010-08-12 |
Dorian Bevec |
Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
|
KR20100057641A
(ko)
|
2007-09-11 |
2010-05-31 |
몬도바이오테크 래보래토리즈 아게 |
인터메딘 47 및 53 펩티드의 치료적 용도
|
KR20100057063A
(ko)
|
2007-09-11 |
2010-05-28 |
몬도바이오테크 래보래토리즈 아게 |
치료제로서의 펩티드의 용도
|
US8293711B2
(en)
|
2007-09-11 |
2012-10-23 |
Pharis Biotech Gmbh |
Use of natriuretic peptides for treating angioedema syndromes
|
EP2205265A1
(en)
|
2007-09-11 |
2010-07-14 |
Mondobiotech Laboratories AG |
Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent
|
WO2009040036A2
(en)
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Use of a peptide as a therapeutic agent
|
US8357656B2
(en)
|
2007-09-15 |
2013-01-22 |
Mayo Foundation For Medical Education And Research |
Natriuretic peptide receptor-C agonists
|
JP2011504506A
(ja)
|
2007-11-21 |
2011-02-10 |
バイオマリン ファーマシューティカル インコーポレイテッド |
C型ナトリウム利尿ペプチドの変異体
|
WO2009086126A2
(en)
|
2007-12-21 |
2009-07-09 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
EP2080812A1
(en)
|
2008-01-18 |
2009-07-22 |
Transmedi SA |
Compositions and methods of detecting post-stop peptides
|
SI2277890T1
(sl)
|
2008-05-23 |
2016-04-29 |
Daiichi Sankyo Company, Limited |
Peptid, sposoben podaljšanja razpolovne dobe peptida, ki je zanimiv, v plazmi
|
US20110152194A1
(en)
|
2008-06-06 |
2011-06-23 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
|
WO2009156481A1
(en)
|
2008-06-25 |
2009-12-30 |
Ascendis Pharma As |
Pegylated bnp
|
KR20190128002A
(ko)
|
2008-06-26 |
2019-11-13 |
악셀레론 파마 인코포레이티드 |
액티빈-actriia 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
|
EP2307447B1
(en)
|
2008-07-02 |
2016-03-09 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides with unique pharmacologic profiles
|
WO2010011096A2
(en)
|
2008-07-23 |
2010-01-28 |
Hanmi Pharmaceutical Co., Ltd. |
A polypeptide complex comprising non-peptidyl polymer having three functional ends
|
US20100093678A1
(en)
|
2008-10-10 |
2010-04-15 |
The University Of Georgia Research Foundation, Inc |
Compositions and methods of the treatment of obesity and osteoporosis
|
WO2010048308A2
(en)
|
2008-10-24 |
2010-04-29 |
Deborah Dickey |
Natriuretic polypeptides
|
WO2010078325A2
(en)
|
2008-12-29 |
2010-07-08 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides for reducing or preventing restenosis
|
AR075029A1
(es)
|
2009-01-19 |
2011-03-02 |
Hanmi Pharm Ind Co Ltd |
Metodo para producir una proteina o un peptido fisiologicamente activo usando un fragmento de inmunoglobulina
|
US20120093814A1
(en)
|
2009-03-30 |
2012-04-19 |
Boehringer Ingelheim International Gmbh |
Fusion Proteins Comprising Canine FC Portions
|
WO2010129655A2
(en)
|
2009-05-05 |
2010-11-11 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides having mutations within their disulfide rings
|
EP3175863B1
(en)
|
2009-05-20 |
2021-12-01 |
BioMarin Pharmaceutical Inc. |
Variants of c-type natriuretic peptide
|
CA2797865A1
(en)
|
2010-04-30 |
2011-11-03 |
Alexion Pharma International Sarl |
Methods, compositions, and kits for the treatment of matrix mineralization disorders
|
US9266939B2
(en)
|
2010-12-27 |
2016-02-23 |
Alexion Pharmaceuticals, Inc. |
Compositions comprising natriuretic peptides and methods of use thereof
|
CA2852874A1
(en)
|
2011-10-19 |
2013-04-25 |
Alexion Pharma Holding |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
CA2854911C
(en)
|
2011-11-10 |
2019-09-24 |
Kai Pharmaceuticals, Inc. |
Calcimimetics and methods for their use
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
JP2015526423A
(ja)
|
2012-07-25 |
2015-09-10 |
サイオクサス セラピューティクス リミテッド |
カヘキシア及びサルコペニアを治療するためのs−ピンドロールの使用
|
US10570380B2
(en)
|
2014-01-24 |
2020-02-25 |
Am-Pharma B.V. |
Downstream processing of an alkaline phosphatase
|
BR112016028567A2
(pt)
|
2014-06-09 |
2018-01-30 |
Kyowa Hakko Kirin Co Ltd |
método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação óssea
|
US10822596B2
(en)
|
2014-07-11 |
2020-11-03 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for treating craniosynostosis
|
JP6787894B2
(ja)
|
2014-12-05 |
2020-11-18 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
組換えアルカリホスファターゼを用いた発作の処置
|
CA2973883A1
(en)
|
2015-01-28 |
2016-08-04 |
Alexion Pharmaceuticals, Inc. |
Methods of treating a subject with an alkaline phosphatase deficiency
|
CN108350440A
(zh)
|
2015-08-17 |
2018-07-31 |
阿雷克森制药公司 |
碱性磷酸酯的制造
|
EP3355904A4
(en)
|
2015-09-28 |
2019-06-12 |
Alexion Pharmaceuticals, Inc. |
IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
|
WO2017074466A1
(en)
|
2015-10-30 |
2017-05-04 |
Alexion Pharmaceuticals, Inc. |
Methods for treating craniosynostosis in a patient
|
US11065306B2
(en)
|
2016-03-08 |
2021-07-20 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children
|
WO2017171871A1
(en)
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
MX2018011833A
(es)
|
2016-04-01 |
2019-02-13 |
Alexion Pharma Inc |
Tratamiento para la debilidad muscular con fosfatasas alcalinas.
|
US10898549B2
(en)
|
2016-04-01 |
2021-01-26 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
WO2017214130A1
(en)
|
2016-06-06 |
2017-12-14 |
Alexion Pharmaceuticals, Inc. |
Metal impact on manufacturing of alkaline phosphatases
|
EP3474886B1
(en)
|
2016-06-27 |
2021-08-04 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children and adolescents
|
EP3500289A4
(en)
|
2016-08-18 |
2020-05-06 |
Alexion Pharmaceuticals, Inc. |
METHODS OF TREATING TRACHEOBRONCHOMALACIA
|